Eli Lilly and Company
CD200R agonist antibodies and uses thereof
Last updated:
Abstract:
The present invention relates to anti-human CD200R agonist antibodies, and uses thereof for treating diseases such as atopic dermatitis, chronic spontaneous urticaria, allergy, asthma, scleroderma, IBD, SLE, MS, RA, GvHD, or psoriasis.
Status:
Grant
Type:
Utility
Filling date:
11 Sep 2019
Issue date:
3 May 2022